Table 1.

Reported cases of MDS/acute leukemia by WHO criteria in patients with Ph-negative clones treated with imatinib

ReferencePh-cytogeneticsDiagnosisCharacteristicsPrevious treatment
Current report, patient 2 –7 AML IFN/cytarabine, HU, imatinib, AMN-107
Perel et al20 Complex* AML No dysplastic features IFN/imatinib
Chee et al18 Complex* AML HU, IFN, BMT, DLI, imatinib
Current report, patient 1 –7 MDS (RAEB-2) → AML HU, imatinib
Current report, patient 3 Complex MDS (RAEB-2) → AML IFN/cytarabine, imatinib
Perel et al20 –7 MDS/AML (> 20% blasts) No dysplastic features IFN/imatinib
Bacher et al21 –7 MDS (RAEB-2) IFN/cytarabine, HU, imatinib
Patchenko et al15 +8 MDS (RAEB-2) Spontaneous improvement in dysplastic changes? HU, imatinib
Bacher et al21 –7 MDS (RARS) Busulfan, IFN, HU, imatinib
Meuss et al22 –7, +8 MDS RA IFN, auto BMT, imatinib
Bumm et al14 –7 MDS Severe dysplasia HU, IFN, imatinib
Bumm et al14 t(3,21) MDS 10% blasts Ida/cytarabine, HU, IFN, imatinib
Mozziconacci et al23 5q-/7q- MDS IFN, ROAP, auto BMT, imatinib
O'Dwyer et al24 inv(1)(p32.3p31.2),del(10)(q22q22) MDS 7% blasts IFN, imatinib
Alimena et al17 +8 MDS HU, imatinib
Jin Huh et al25 Diploid ALL HU, IFN, imatinib
Cherrier-De Wilde et al19 Diploid ALL HU, IFN, imatinib
  • — indicates none; IFN, interferon-α; HU, hydroxyurea; BMT, bone marrow transplantation; Ida, idarubicin; and ROAP, rubidomycine, vincristine, cytosine arabinoside, prednisone

  • * Included monosomy 7 among the chromosomal aberrations

  • Including del5(q13q31)